论文部分内容阅读
莫索尼啶(Moxonidine)是一种具中枢作用的α_2受体激动剂,具降压作用。本文研究了莫索尼啶在人体内的药动学和药效学。 8例高血压患者,血压20.54±1.2/13.0±0.9kPa,病程2.5～10年,参试前2周停用抗高血压药。试验采取单盲、安慰剂对照方案,受试者于第1天早晨口服安慰剂1片,次日晨口服莫索尼啶1片0.25mg,试验中定期测量血压和心率,定期测定血浆肾素活性和去甲肾上腺素、肾上腺素浓度,并用咬持棉卷称重法测定唾液分泌量,用直观评分法评定药物对受试者的镇静作用。结果:口服莫索尼啶的血药浓度t_(max)为1.07±0.79小
Moxonidine is a centrally acting alpha-2 receptor agonist with a hypotensive effect. This article studies the pharmacokinetics and pharmacodynamics of Moxonidine in humans. Eight patients with hypertension, blood pressure 20.54 ± 1.2 / 13.0 ± 0.9kPa, duration of 2.5 to 10 years, two weeks before the trial disable antihypertensive drugs. The study was a single-blind, placebo-controlled regimen. Subjects took 1 placebo tablet on the morning of the first day and 0.25 mg moxonidine on the next morning. Blood pressure and heart rate were measured regularly and plasma renin activity was measured periodically And norepinephrine, epinephrine concentration, and bite cotton swab weighing salivary secretion, the use of visual scoring method to assess the sedative effect of the drug on the subjects. Results: The plasma concentration of oral Moxonidine t_ (max) was 1.07 ± 0.79 small